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Expression of cyclooxygenase (COX)-2 plays a key role in tumorigenesis and development and peroxisome proliferator-activated
receptor g (PPARg) has been implicated in the control of COX-2 expression in some tissues. The aim of this study is to investigate
(1) whether expression of COX-2 and PPARg is associated with ovarian carcinogenesis and progression of ovarian tumours and (2)
whether COX-2 expression is controlled through ligand-mediated activation of PPARg in ovarian carcinoma cells. For this purpose,
the presence of COX-2 and PPARg was immunohistochemically examined in 71 epithelial ovarian carcinomas, 18 borderline tumours
and 23 benign tumours and the levels of COX-2 and PPARg proteins were determined by enzyme immunoassay in four benign
tumours, three borderline tumours and 12 carcinomas. The frequency of COX-2 and PPARg detection was significantly increased
and decreased as lesions progressed to carcinoma, respectively. The COX-2 protein was not detected in the three borderline
tumours, whereas PPARg protein was detected in all of them. COX-2 protein was detected in eight of the 12 carcinomas, whereas
PPARg protein was detected in only two cases. In addition, PPARg protein was not detected in all of the eight carcinomas in which
COX-2 protein was detected, suggesting that expression of PPARg and COX-2 was in a reciprocal relationship. Furthermore, in
cultured ovarian carcinoma cells, Western blot revealed that PPARg and COX-2 expression was regulated conversely as a result of
stimulation by 15-deoxy-D
12, 14 PGJ2 (15-PGJ2), a PPARg activator. In addition, 15d-PGJ2 suppressed tumour necrosis factor-a-
induced-COX-2 expression, confirming the reciprocal correlation between COX-2 and PPARg. From these results, it was suggested
that PPARg activation might suppress COX-2 expression via the nuclear factor-kB pathway in the ovarian carcinoma cells and that
low expression of PPARg and high expression of COX-2 might be involved in carcinogenesis and progression of ovarian tumours.
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Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandin
(PG) synthesis because of its rapid autoinactivation (Smith and
Marnett, 1991). COX has two isoforms, the constitutive COX-1 and
the inducible COX-2 (O’Banion et al, 1992). COX-1 is expressed in
most tissues, whereas COX-2 is largely absent but is responsible
primarily for PGs produced in inflammatory sites, suggesting that
COX-2 plays a critical role in inflammation (Smith et al, 1996).
Epidemiological studies have shown 40–50% reduction in
mortality from colorectal carcinoma in continuous users of
nonsteroid anti-inflammatory drugs (NSAIDs) compared with that
of noncontinuous users (Thun et al, 1991; Giovannucci et al, 1995).
Antitumour effect of NSAIDs was caused by inhibition of COX-2
(Taketo, 1998). COX-2 is known to be a promoter of gastro-
intestinal carcinoma. Many studies suggest that overexpression of
COX-2 might be involved in multistep carcinogenesis and tumour
progression especially in gastric and colorectal carcinoma
(Prescott and White, 1996; van Rees et al, 2002). Recently, a
progressive development from ovarian serous tumours of low
potential malignancy to invasive serous carcinoma has been
suggested in parallel to the concept of adenoma–carcinoma
sequence in colorectal carcinomas (Hauptmann and Dietel,
2001), although the concept that ovarian carcinogenesis is a linear
pathway as for colorectal carcinoma is still contentious. Shigemasa
et al (2003) reported that COX-2 expression might play an
important role in ovarian carcinoma development. Ferrandina et al
(2002) described that increased COX-2 expression was associated
with chemotherapy resistance and outcome in ovarian carcinoma
patients and then Denkert et al (2002) reported that COX-2
expression was an independent prognostic factor in ovarian
carcinoma. More recently, COX-1 has been reported to contribute
to carcinoma development in the ovary through stimulation of
neovascularisation (Gupta et al, 2003).
Peroxisome proliferator-activated receptor g (PPARg)i sa
member of a nuclear hormone receptor superfamily that can
modulate gene expression upon ligand binding (Subbaramaiah
et al, 2001). Ligand-mediated activation of PPARg has been linked
to cellular differentiation, apoptosis and anti-inflammatory
responses. In colon carcinoma cells, ligand activation of the
receptor inhibits cell growth, induces a differentiation response
and reverses the malignant phenotype (Sarraf et al, 1998). PPARg
agonists and PPARg overexpression led to a drastic reduction of
the cell growth rate in PPARg-expressing thyroid carcinoma cells
(Martelli et al, 2002). The nuclear prostanoid 15-deoxy-D
12, 14 PGJ2
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(Forman et al, 1995; Kliewer et al, 1995). 15d-PGJ2 was found to
induce apoptosis, inhibit proliferation and prevent the growth of
human breast carcinoma cells in the nude mouse model (Clay et al,
1999). Inhibition of COX-2 and activation of PPARg inhibited the
development of rat mammary gland carcinogenesis (Suh et al,
1999; Harris et al, 2000). Additionally, independent studies showed
that COX-2 and PPARg are induced and inactivated, respectively,
in human breast carcinoma (Jiang et al, 2000; Ristimaki et al,
2002). Inoue et al (2000) proposed that expression of COX-2 was
regulated by a negative feedback loop mediated through PPARg in
macrophages. Badawi and Badr (2003) described that the altered
expression of COX-2 and PPARg might influence the development
of human breast carcinoma and its progression to metastasis.
Recently, PPARg has been reported to be localised primarily to
granulosa cells in ovarian tissue and to be involved in follicular
development (Komar et al, 2001).
The present study was designed to investigate whether expres-
sion of COX-2 and PPARg is associated with ovarian carcinogen-
esis and progression of ovarian tumours. We also examined
whether COX-2 expression was controlled through ligand-
mediated activation of PPARg in ovarian carcinoma cells. This is
the first report describing the relationship between expression of
COX-2 and PPARg in ovarian malignancies.
MATERIALS AND METHODS
Study population and tissues
Immunohistochemical examination was performed retrospectively
on 112 epithelial ovarian tumours obtained from women who were
surgically treated at the Hirosaki University Hospital between 1989
and 2003 after informed consent had been obtained. The tissue
specimens included 71 carcinomas, 18 borderline tumours and 23
benign cystadenomas. All patients with epithelial ovarian carci-
noma were surgically staged in accordance with the 1988
International Federation of Gynecology and Obstetrics (FIGO)
criteria. Patients included in this study had not received any
preoperative chemotherapy. The breakdown for stages of ovarian
carcinomas consisted of 40 patients with stage I, seven with stage
II, 18 with stage III, six with stage IV. Histological types were
classified into 30 cases with serous cystadenocarcinoma, 11 with
mucinous cystadenocarcinoma, 17 with endometrioid adenocarci-
noma, 12 with clear cell adenocarcinoma and one with undiffer-
entiated adenocarcinoma. All patients with ovarian carcinoma
received postoperative chemotherapy combining cisplatin
(60mgm
 2), epirubicin (40mgm
 2) and cyclophosphamide
(300mgm
 2). The duration of follow-up ranged from 8 to 156
months (median, 54 months). The mean age of patients with
ovarian carcinoma at surgery was 54.1 years (range, 28–78 years).
Of the 18 borderline tumours, four were serous and 14 mucinous.
Of the 23 benign cystadenomas, nine were serous and 14
mucinous.
Immunohistochemical staining of COX-2 and PPARc
Anti-COX-2 (Immuno-Biological Laboratories, Gunma, Japan) and
anti-PPARg (Cayman Chemical, Ann Arbor, MI, USA) antibodies
were used at a concentration of 5mgml
 1, respectively. All samples
surgically obtained for immunohistochemistry were immediately
fixed in formaldehyde and embedded in paraffin. Sections 6mm
thick were routinely passed through xylene and a graded alcohol
series and placed in 0.01 M citrate buffer, pH 6.0, and heated at
500W in a microwave oven for 5min to retrieve tissue antigen. The
sections were treated with 0.3% hydrogen peroxide (H2O2)i n
methanol for 10min to quench the endogenous peroxidase activity
within the tissue. Nonspecific binding sites were blocked with 1%
bovine serum albumin (BSA) and 20% heat-inactivated goat serum
in phosphate-buffered saline (PBS) for 30min at room temperature
(RT). The sections were then stained for COX-2 or PPARg by the
avidin–biotin–peroxidase complex method using the appropriate
antibodies as reported previously (Yokoyama et al, 2003). Anti-
COX-2 antibody was applied for 12h at 41C in a moist chamber.
Anti-PPARg antibody was applied for 1h at 371C. The binding sites
of peroxidase were visualized with 0.02% diaminobenzidine (DAB)
(Sigma-Aldrich, St Louis, MO, USA) as a chromogen in Tris-HCl
buffer, pH 7.6 containing 0.03% H2O2. The sections were then
counterstained with haematoxylin for microscopic examination.
As negative control, preimmune rabbit serum was used instead of
the antibody. As positive control for COX-2 and PPARg staining,
formalin-fixed paraffin-embedded sections of colon carcinoma and
urinary bladder carcinoma were stained by the same procedure,
respectively. Two observers (AS and YY) independently evaluated
and interpreted the results of immunohistochemical staining,
without the knowledge of the clinical data of each patient. Cases in
which more than 10% of tumour cells were as strongly
immunoreactive as positive control cells were considered positive.
Measurement of levels of COX-2 and PPARc
Analysis of levels of COX-2 and PPARg in the ovarian tumours was
carried out by enzyme immunoassay (EIA). Four benign tumours,
three borderline tumours and 12 carcinomas kept at  801C were
used for this experiment. For measurement of COX-2 and PPARg
levels, the tissue specimens (100mg) were minced, sonicated in
10mM Tris-HCl, pH 7.4, 0.5 M NaCl and centrifuged at 10000g for
15min at 41C to separate cell debris and the fat layer. The resulting
supernatants were used for analysis. EIA for COX-2 and PPARg
was carried out using a human COX-2 assay kit (Immuno-
Biological Laboratories, Gunma, Japan) and a TransAMt PPARg
Transcription Factor Assay kit (Active Motif, Carlsbad, NM, USA),
respectively, according to each manufacturer’s instruction. Colour
intensity was measured at 450nm using BIORAD Model 550
microplate reader (Bio-Rad Laboratories, Tokyo, Japan) and the
levels of COX-2 and PPARg were expressed as ng per mg protein
and mg per cell extract per well, respectively. The range of
measurement sensitivity in COX-2 and PPARg levels is 2.15 to
275ngml
 1 and 0.75 to 7.5mg(cell extract)
 1(well)
 1, respectively.
Standard curves and positive and negative controls were generated
for COX-2 and PPARg and assayed simultaneously with the
samples.
Cell culture
OVCAR-3 cells were obtained from the American Type Culture
Collection and the ovarian carcinoma cell line, which was derived
from serous adenocarcinoma and was established at the Hirosaki
University Hospital, was used. Cells were seeded at 1.2 10
4
cellscm
 2 and grown in RPMI 1640 medium supplemented with
10% (vv
 1) fetal bovine serum (FBS), 100Uml
 1 penicillin and
100mgml
 1 streptomycin, at 371C in a water-saturated atmo-
sphere with 5% CO2/95% air.
15d-PGJ2 treatment
After 24h, the medium was replaced by the fresh medium (10%
FBS) containing 15d-PGJ2 (Alexis Biochemicals, San Diego, CA,
USA) at a final concentration of 0.1, 1, 10 or 20mM. Cells were
exposed to 15d-PGJ2 at the indicated concentrations for 72h of
treatment. As a negative control, cells were cultured in a medium
without 15d-PGJ2. For each cell culture set, expression of COX-2
and PPARg in 15d-PGJ2-treated and untreated cells was examined
using Western blot analysis.
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The medium was replaced with serum-free medium 12h before
stimulation. OVCAR-3 cells were then treated with 20ngml
 1
tumour necrosis factor (TNF)-a (Strathmann Biotec AG, Hamburg,
Germany) in the presence or absence of 20mM 15d-PGJ2 for 24h.
As a negative control, cells were cultured in a medium without
TNF-a and 15d-PGJ2. For each cell culture set, expression of COX-2
was examined using Western blot analysis.
Western blot analysis
For Western blot analysis, cells were washed with PBS after the
incubation period, scraped into 10mM Tris-HCl, pH 7.4, 0.5 M
NaCl, and sonicated three times for 30s using Ultra S Homo-
genizer model (Taitec, Nagoya, Japan). After centrifugation at
10000g for 15min at 41C, the supernatants were used for protein
assay. The protein concentration was determined using Bradford
method. The protein samples (50mg) were run through 12.5%
sodium dodecyl sulphate (SDS)–polyacrylamide gel electrophor-
esis. After electrophoretic transfer of the protein to nitrocellulose
membrane, nonspecific binding was blocked by incubation with
3% gelatin in 20mM Tris-HCl, pH 7.5, 0.5 M NaCl (TBS) for 1h at
RT. After being washed three times with TBS containing 0.05%
Tween 20 (TTBS), the blots were probed with a rabbit polyclonal
IgG specific for human COX-2 (Immuno-Biological Laboratories,
Gumma, Japan) or a PPARg polyclonal antibody (Cayman
Chemical, Ann Arbor, MI, USA) for 2h. The blots were also
probed with a monoclonal anti-b-actin antibody (SIGMA, St Louis,
MO, USA) to be relatively quantified. b-Actin was used as a loading
control. The membranes were then washed three times with TTBS
and incubated for 1h at RT with a biotinylated anti-rabbit
immunogloblin (Vector Laboratories, Burlingame, CA, USA) for
COX-2 and PPARg and a biotinylated anti-mouse immunogloblin
(Vector Laboratories, Burlingame, CA, USA) for (b-actin, respec-
tively. After being washed three times with TTBS, the membrane
were transferred to VECTERSTA1N ABC Reagent (Vector Labora-
tories, Burlingame, CA, USA) and incubated in this solution for
30min at RT. Diaminobenzidine was used as a substrate of
peroxidase.
Statistical analysis
Statistical analysis was carried out by w
2-test or Fisher’s exact
probability test. A result was deemed significant at Po0.05.
RESULTS
Detection of COX-2 and PPARc in benign, borderline
tumours and carcinoma
COX-2 and PPARg were homogeneously stained in the cytoplasm
of tumour cells in positive cases (Figure 1). The frequencies of
COX-2 and PPARg detection in ovarian tumours are demonstrated
in Table 1. There was no significant difference in COX-2 positivity
between samples of benign and borderline tumours (Table 1). The
incidence of COX-2 detected in carcinomas was significantly
higher than that detected in benign tumours (Table 1, Po0.02) and
higher with a marginal significance than that detected in border-
line tumours (Table 1, P¼0.058). On the other hand, the frequency
of PPARg detected in borderline tumours was significantly higher
than that detected in benign tumours and carcinomas, respectively
(Table 1, Po0.0001, Po0.01, respectively).
COX-2 and PPARg positivity in carcinomas was not correlated
with clinical factors such as stage, histological type, lymph node
metastasis and recurrence (Table 2).
Determination of COX-2 and PPARc protein levels in
ovarian tumour tissues
Levels of COX-2 and PPARg proteins were determined by EIA in
four benign tumours, three borderline tumours and 12 carcino-
mas. COX-2 and PPARg proteins were not detected in the benign
tumours at all (Table 3). The COX-2 protein levels of the three
borderline tumours were below the measurement sensitivity,
whereas PPARg protein was detected in all of those ones
(Table 3). COX-2 protein was detected in eight of the 12
carcinomas and the remaining four carcinomas lacked COX-2
protein (Table 3). In contrast, 10 of the 12 carcinomas lacked
PPARg protein and PPARg protein was detected in only two
carcinomas (Table 3). The level of PPARg protein was below the
measurement sensitivity in all of the eight carcinomas in which
COX-2 protein was detected, whereas COX-2 protein lacked in the
two carcinomas in which PPARg protein was detected (Table 3).
Figure 1 Immunohistochemical staining of COX-2 and PPARg in ovarian
carcinoma. Positive staining of COX-2 (A) and PPARg (B) in carcinoma
tissues (scale bar, 50mm). They are representative of all the positive
samples. Tissues demonstrated in (A) and (B) are a serous adenocarci-
noma.
Table 1 Detection of COX-2 and PPARg in ovarian tumours
Tissue
No. of
cases
Case no. (%)
of COX-2 positive
Case no. (%)
of PPARc positive
Benign tumour 23 3 (13.0) 1 (4.5)
Borderline tumour 18 3 (16.7) 14 (77.8)
Carcinoma 71 28 (39.4) 31 (43.7)
The incidence of COX-2 detected in carcinomas was significantly higher than that
detected in benign tumours (Po0.02) and higher with a marginal significance than
that detected in borderline tumours (P¼0.058). The frequency of PPARg detected
in borderline tumours was significantly higher than that detected in benign tumours
and carcinomas, respectively (Po0.0001, Po0.01, respectively).
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cultured ovarian carcinoma cells
To examine whether COX-2 expression is controlled through
PPARg activation in ovarian carcinoma cells, OVCAR-3 cells and
the ovarian carcinoma cells established at our hospital were
cultured in a semiconfluent state in normal culture medium or in
media supplemented with 0.1–20mM 15d-PGJ2, a PPARg activator
as described in Materials and Methods. Western blot analysis
revealed that expression of PPARg and COX-2 was increased and
decreased, respectively according to 15d-PGJ2 concentrations
(Figure 2), suggesting that 15d-PGJ2 activated PPARg in both cell
lines and PPARg activation might result in suppression of COX-2
expression in the cells. Results shown in Figure 2 are representa-
tive of two separate experiments with two cell lines. b-Actin was
used as a loading control.
Suppressive effect of 15d-PGJ2 on cytokine-induced COX-2
expression in cultured ovarian carcinoma cells
TNF-a, an inflammatory cytokine, is known to increase COX-2
expression via nuclear factor NFkB pathway. To examine whether
NFkB pathway is related to the signalling between PPARg activation
and COX-2 expression, OVCAR-3 cells were cultured in a semicon-
fluent state in normal culture medium or in media supplemented with
TNF-a i nt h ep r e s e n c eo ra b s e n c eo f2 0mm1 5 d - P G J 2 as described in
Materials and Methods. Tumour necrosis factor-alpha induced COX-2
expression in OVCAR-3 cells (Figure 3). Addition of 15d-PGJ2 to the
media supplemented with TNF-a suppressed TNF-a-induced-COX-2
expression (Figure 3). b-Actin was used as a loading control.
DISCUSSION
The present study clearly demonstrated that the frequency and the
degree of PPARg expression were significantly decreased as lesions
progressed from a borderline tumour to carcinoma, and those of
COX-2 expression were significantly increased as lesions pro-
gressed from a benign tumour to carcinoma, suggesting that low
expression of PPARg and high expression of COX-2 in precancer-
ous lesions might be involved in progression of ovarian tumours to
carcinoma. Independent studies have shown that induction of
COX-2 and inactivation of PPARg occurred during the develop-
ment and progression of human breast carcinoma (Jiang et al,
2000; Ristimaki et al, 2002). On the other hand, inhibition of COX-
2 and activation of PPARg has been shown to prevent mammary
carcinogenesis in experimental animals (Suh et al, 1999; Harris
et al, 2000). Additionally, COX-2 selective inhibitors and PPARg
ligands could significantly attenuate the growth of human breast
carcinoma cells (Elstner et al, 1998; Howe et al, 2001). Thus it has
been suggested that high expression of PPARg and low expression
of COX-2 in the tumours might be involved in attenuating the
capacity of the tumours to develop more malignant nature. Badawi
and Badr (2003) described that an increase of COX-2 expression
and a decrease of PPARg expression in breast carcinoma tissues
were paralleled by increases in the tissue levels of PGE2 and
decreases in 15d-PGJ2 and their altered expressions might
influence the development of human breast carcinoma.
COX-2 overexpression has been observed in many tumour types
including gynaecological malignancies. Mechanistic study sug-
gested that expression of COX-2 in uterine cervical carcinoma cells
downregulated apoptotic processes and thus enhanced tumour
invasion and metastasis (Affney et al, 2001). Li et al (2004)
described that while COX-2 protein was not detected in normal
Table 2 Correlation between expression of COX-2 and PPARg and
clinicopathological factors in ovarian carcinoma
Factor
No. of
cases
Case no. (%)
of COX-2
positive
Case no. (%)
of PPARc
positive
Stage
I/II 47 20 (42.6) 21 (44.7)
III/IV 24 8 (33.3) 9 (37.5)
Histological type
Serous 30 14 (46.7) 10 (33.3)
Mucinous 11 3 (27.3) 6 (54.5)
Endometrioid 17 6 (353) 10 (58.8)
Clear cell 12 5 (41.7) 4 (33.3)
Undifferentiated 1 0 0
Lymph node metastasis
Positive 10 6 (60.0) 4 (40.0)
Negative 61 22 (36.1) 26 (42.6)
Outcome
Recurrent 19 6 (41.6) 8 (42.1)
Nonrecurrent 52 22 (42.3) 22 (42.3)
COX-2 and PPARg positivity in carcinomas was not correlated with clinical factors
such as stage, histological type, lymph node metastasis and recurrence.
Table 3 Determination of COX-2 and PPARg proteins in ovarian
tumours
Tissue Case
Amount of
COX-2 protein
(ng per mg
protein)
Amount of
PPARc
protein (lg
(cell extract)
 1
(well)
 1)
Benign cystadenoma 1 ND ND
2N D N D
3N D N D
4N D N D
Borderline tumour 1 ND 92.9
2 ND 74.7
3 ND 57.9
Carcinoma 1 3.91 ND
2 3.69 ND
3 2.65 ND
4 2.32 ND
5 2.22 ND
6 1.98 ND
7 1.72 ND
8 1.25 ND
9N D N D
10 ND ND
11 ND 70.1
12 ND 60.2
ND stands for not detectable.
15d-PGJ2 AB
0
PPAR
COX-2
-Actin
0.1 1 10 20 M 0 0.1 1 10
57 kDa
74 kDa
20 M
15d-PGJ2
Figure 2 Effect of 15d-PGJ2 on COX-2 and PPARg expression in
OVCAR-3 (A) and the ovarian carcinoma cell line established at our
institute (B). In both cell lines, PPARg expression was increased according
to 15d-PGJ2 concentrations, whereas COX-2 expression was decreased
according to 15d-PGJ2 concentrations. Results shown are representative of
two separate experiments with two cell lines, b-Actin was used as a loading
control.
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lepithelium of the ovary, its protein was frequently expressed in
ovarian epithelial carcinoma, suggesting that it might contribute to
the carcinoma development or progression. Matsumoto et al
(2001) found a significant correlation between expression of
vascular endothelial growth factor (VEGF) and COX-2 in ovarian
neoplasms and suggested that an increased expression of COX-2
might be associated with malignant transformation and tumor-
igenesis through the activation of VEGF. Denkert et al (2002)
reported that expression of COX-2 was immunohistochemically
detected in 42% of ovarian carcinomas and in 37% of borderline
tumors, and described that COX-2 expression was an independent
prognostic factor in human ovarian carcinoma. Although we found
high frequency of COX-2 expression in ovarian carcinoma, we did
not show the close relationship between expression of COX-2 and
metastasis or recurrence in ovarian carcinoma. Large-scale
prospective and retrospective studies are needed to clarify whether
COX-2 expression is of practical utility as a prognostic factor.
PPARg plays a crucial role in apoptosis and differentiation of a
variety of cells. Induction of differentiation has been observed in
several malignant cells as a result of stimulation by PPARg
(Mueller et al, 1998). PPARg activation resulted in apoptosis of
choriocarcinoma cells (Keelan et al, 1999), prostate carcinoma
cells (Kubota et al, 1998), leukaemic cells (Asou et al, 1999) and
gastric carcinoma (Sato et al, 2000). More recently, Martelli et al
(2002) reported that arrest of G1 cell cycle was observed and
apoptosis was induced in thyroid carcinoma cells transfected with
PPARg. Breast carcinoma cells treated with PPARg agonist show
dramatic morphological changes, and express E-cadherin and b-
casein, markers of breast cell differentiation (Elstner et al, 1998;
Clay et al, 1999). Furthermore, it has been reported that
differentiation and reversal of malignant changes were induced
in CX-1 colonic tumour cells treated with PPARg agonist in Swiss
nude mice (Sarraf et al, 1998). Zander et al (2002) described that
activation of PPARg transiently induced N-cadherin, the glioma
differentiation marker, in human and rat glioma cells and in
parallel, a subset of surviving cells showed de novo outgrowth of
processes resembling astrocyte-like morphology based on PPARg
activation. Taking these results together including ours, activation
of PPARg and inhibition of COX-2 may be favourable for guiding
neoplastic cells towards redifferentiation.
PPARg signalling has been implicated in the control of COX-2
expression in certain tissues, although the exact mechanism that
underlies PPARg regulation of COX-2 expression remains to be
elucidated. To date, there are several reports suggesting a
reciprocal interaction between COX-2 expression and PPARg
activity (Inoue et al, 2000; Ikawa et al, 2001; Yang and Frucht,
2001). However, it is still unclear whether COX-2 expression is
controlled through PPARg signalling in ovarian carcinoma cells.
We investigated whether PPARg activity was involved in COX-2
regulation in human ovarian carcinoma cells, and found that 15d-
PGJ2, a PPARg ligand, reduced COX-2 expression in a dose-related
manner, suggesting that COX-2 expression was regulated through
PPARg activity in ovarian carcinoma cells. The inhibitory effect of
PPARg activation on COX-2 expression is also reported in HT-29
human colon carcinoma cells (Yang and Frucht, 2001). Further-
more, it has been shown that NSAID suppress IL-1b-induced COX-
2 expression (Xu et al, 1999), and inhibits TNF-a-induced COX-2
expression (Paik et al, 2000), suggesting that expression of COX-2
is under the control mechanisms by both cytokines and PPARg
systems. In fact, Inoue et al (2000) demonstrated that 15d-PGJ2
suppressed COX-2 promoter activity by interfering with the NFkB
signalling pathway, and that transfection of a PPARg expression
vector into the endothelial cells resumes the suppressive regulation
of COX-2 gene by 15d-PGJ2. Tumour necrosis factor-alpha is a
strong inducer of COX-2 expression by stimulating the NFkB
system (Yamamoto et al, 1995). As shown in Figure 3, the present
result showed that COX-2 was induced by TNF-a in ovarian
carcinoma cells and that TNF-a-induced COX-2 expression was
suppressed by 15d-PGJ2, suggesting that COX-2 expression was
under the control of PPARg and NFkB pathway in the ovarian
carcinoma.
In conclusion, the reciprocal correlation between COX-2 and
PPARg found in the present study implicates that COX-2 and
PPARg may contribute to ovarian carcinoma induction. Thus, the
present results suggested that ligand-mediated PPARg activation
suppressed COX-2 expression via the NFkB pathway in the ovarian
carcinoma cells, and that high expression of PPARg and low
expression of COX-2 might play an important role in inhibiting
ovarian carcinogenesis.
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